- Par-4 for Molecular Therapy of Prostate Cancer. J. Butler; V.M. Rangnekar // Current Drug Targets;Apr2003, Vol. 4 Issue 3, p223
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths in American men. Although many treatment measures such as androgen deprivation, radiation therapy, and cryoablation exist for primary prostate cancer, there is currently no effective...
- Targeted therapy: Pros and cons of dependency. Hutchinson, Ezzie // Nature Reviews Cancer;Sep2003, Vol. 3 Issue 9, p633
Focuses on prostate cancer. Cells which are present in an untreated prostate cancer; Impact on cancer cells when a patient is treated with androgen-ablation therapy; Agents that activate apoptosis in prostate cancer cells.
- Intermittent androgen withdrawals as effective as continuous. Susman, Ed // Urology Times;Sep2002, Vol. 30 Issue 9, p13
Compares the efficacy of intermittent androgen deprivation versus continuous androgen deprivation in the treatment of advanced prostate cancer. Reduced frequency and severity of adverse events; Lower disease progression rate; Improvement of quality of life.
- Fewer Prostate Cancer Patients Are Initiating ADT, Data Shows. // Renal & Urology News;Feb2012, Vol. 11 Issue 2, p24
The article reports on the decline on the use of androgen deprivation therapy (ADT) for prostate cancer (PCa).
- Androgen-Independent Prostate Cancer: Potential Role of Androgen and ErbB Receptor Signal Transduction Crosstalk. // Neoplasia;Mar/Apr2003, Vol. 5 Issue 2, p99
Summarizes evidence of the functionality of androgen receptor (AR) signalling in prostate cancer under conditions of maximal androgen blockade. Information on prostate cancer; Background on AR; role of the phsophorylation of phosphatidylinositol at the D3 position in cell survival.
- Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Koivisto, P // Prostate Cancer & Prostatic Diseases;1997, Vol. 1 Issue 1, p21
Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. We recently described androgen receptor (AR) gene amplification in 28% of recurrent prostate carcinomas from hormone-refractory prostate cancer patients. To investigate the hypothesis that amplification...
- Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Pantuck, A J; Zismon, A; Tso, C-L; Belldegrun, A S // Prostate Cancer & Prostatic Diseases;2000, Vol. 3 Issue 4, p280
In most clinical trials of intermittent androgen deprivation (IAD), the decision to stop androgen withdrawal is based on monitoring PSA levels, waiting for its drop to nadir. Based on in vitro pre-clinical studies, a modified â€˜onâ€“offâ€™ schedule of short intervals of androgen...
- The role of androgen receptor coactivators in prostate cancer growth. Taneja, S S // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS38
Upon ligand-binding, the androgen receptor (AR) translocates from the cytosol to the cell nucleus, where it homodimerises to an active configuration capable of transcriptional activation at promoter sites carrying an androgen response element (ARE) consensus sequence. The N-terminal region of AR...
- Intermittent androgen suppression in the management of prostate cancer: a phase II comparative study. Irani, J // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS20
Based on preclinical and phase II non-comparative studies, intermittent androgen suppression (IAS) appears to be a potential alternative to continuous androgen suppression (CAS) in advanced prostate cancer. The aim of this multicentric randomised study is to compare permanent and intermittent...
- Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Eder, Iris E; Culig, Zoran; Ramoner, Reinhold; Thurnher, Martin; Putz, Thomas; Nessler-Menardi, Claudia; Tiefenthaler, Martin; Bartsch, Georg; Klocker, Helmut // Cancer Gene Therapy;Jul2000, Vol. 7 Issue 7, p997
Currently available methods for treatment of human prostatic carcinoma aim to inactivate the androgen receptor (AR) by androgen deprivation or blockade with anti-androgens. Failure of endocrine therapy and tumor progression is characterized by androgenindependent growth despite high levels of AR...